ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain™, a novel treatment for subclinical mastitis without a milk discard requirement that provides an alternative to traditional antibiotics.

Company profile
Ticker
ICCC
Exchange
Website
CEO
Michael Brigham
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
10382980
ICCC stock data
Press releases
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022
11 Aug 22
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
4 Aug 22
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
27 Jul 22
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
7 Jul 22
Investment data
Securities sold
Number of investors
Calendar
11 Aug 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.04M | 11.04M | 11.04M | 11.04M | 11.04M | 11.04M |
Cash burn (monthly) | 257.97K | (no burn) | 227.67K | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 369.47K | n/a | 326.07K | n/a | n/a | n/a |
Cash remaining | 10.67M | n/a | 10.72M | n/a | n/a | n/a |
Runway (months of cash) | 41.4 | n/a | 47.1 | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 8.25 | 400 | 3.3K | 94,019 |
14 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 8.05 | 50 | 402.5 | 93,619 |
14 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 8.1 | 200 | 1.62K | 93,569 |
13 Jun 22 | David Cunningham | Common stock $0.10 per value per share | Buy | Acquire P | No | No | 8 | 1,000 | 8K | 16,000 |
13 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 7.77 | 485 | 3.77K | 93,369 |
13 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 7.82 | 48 | 375.36 | 92,884 |
13 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 7.79 | 90 | 701.1 | 92,836 |
13 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 7.81 | 462 | 3.61K | 92,746 |
13 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 7.8 | 200 | 1.56K | 92,284 |
13 Jun 22 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 7.73 | 200 | 1.55K | 92,084 |
Institutional ownership, Q1 2022
12.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 0 |
Closed positions | 3 |
Increased positions | 9 |
Reduced positions | 10 |
13F shares | Current |
---|---|
Total value | 22.68M |
Total shares | 951.57K |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 204.33K | $1.97M |
Renaissance Technologies | 154.58K | $1.49M |
Meristem Family Wealth | 85.52K | $825K |
Shufro Rose & Co | 82.05K | $792K |
Bleichroeder | 71.07K | $686K |
MS Morgan Stanley | 66.77K | $644K |
Overbrook Management | 45.88K | $443K |
Perritt Capital Management | 36.49K | $352K |
Strategic Financial Services, Inc, | 31K | $299K |
Geode Capital Management | 22.67K | $218K |
Financial report summary
?Management Discussion
- As detailed in Note 17, “Segment Information”, to the accompanying unaudited financial statements, we operate in two business segments. The Scours segment is dedicated to manufacturing and selling First Defense®, a product used to prevent scours in newborn calves, which is regulated by the USDA. The Mastitis segment is focused on developing and commercializing Re-Tain®, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the FDA.
- Through both continued growth in sales of the First Defense® product line and a successful launch of Re-Tain® as soon as possible, and with a measured approach to expanding our customer-facing staff, it is our objective to increase our current annual level of total product sales of approximately $19.2 million for the year ended December 31, 2021 to approximately $23 million or more by the year ending December 31, 2023. As additional resources are dedicated to production, sales, marketing and technical services, our longer-term goal is to exceed $35 million of annual total product sales as soon as possible during the five-year period after the market launch of Re-Tain®.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
abstained, bacterial, birth, brand, breakthrough, broker, buffer, caught, comment, competitor, crop, crucial, differentiating, displace, divert, encouraged, erasing, escalate, feature, frame, fueled, guarantee, healthy, house, inconsistency, inconsistent, intent, internationally, landlord, leader, livestock, message, morbidity, mortality, norm, notify, pharma, plastic, polyclonal, profile, proven, proximity, recession, recessionary, reminded, research, resolve, resolved, satisfaction, Secondarily, shed, shell, substantive, therapeutic, thing, thirty, transform, true, type, unprotected, Urban, worthy
Removed:
accept, batch, deductible, dumped, encountered, executing, extending, forgiven, immunize, implemented, involuntary, legacy, lifting, lunch, pace, Paycheck, payroll, peak, pivotal, PPP, preceding, purified, recurrence, reinspection, repeatability, school, senior, setback, slightly, swap, TD, temporarily, variance
Financial reports
Current reports
8-K
ImmuCell Announces Unaudited Financial Results for
11 Aug 22
8-K
Other Events
27 Jul 22
8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
6 Jul 22
8-K/A
Submission of Matters to a Vote of Security Holders
21 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 22
8-K
ImmuCell Announces Unaudited Financial Results for Q1 2022 Product Sales Increased 46% over Q1 2021
12 May 22
8-K
ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022
11 Apr 22
8-K
Entry into a Material Definitive Agreement
24 Mar 22
8-K
ImmuCell Announces Unaudited Financial Results for Annual Product Sales for 2021 Increased 25% over 2020
22 Feb 22
8-K
Independent Contractor Agreement
11 Feb 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
16 Apr 21
S-8
Registration of securities for employees
27 Mar 20
424B5
Prospectus supplement for primary offering
27 Mar 19
424B5
Prospectus supplement for primary offering
26 Mar 19
424B3
Prospectus supplement
29 Nov 18
S-3
Shelf registration
20 Nov 18
424B5
Prospectus supplement for primary offering
18 Dec 17
424B5
Prospectus supplement for primary offering
26 Jul 17
424B3
Prospectus supplement
14 Dec 16
S-3/A
Shelf registration (amended)
4 Dec 16
Other
EFFECT
Notice of effectiveness
30 Nov 18
CORRESP
Correspondence with SEC
27 Nov 18
UPLOAD
Letter from SEC
25 Nov 18
CORRESP
Correspondence with SEC
13 Dec 16
EFFECT
Notice of effectiveness
13 Dec 16
UPLOAD
Letter from SEC
27 Nov 16
EFFECT
Notice of effectiveness
9 Nov 15
CORRESP
Correspondence with SEC
8 Nov 15
UPLOAD
Letter from SEC
6 Feb 13
CORRESP
Correspondence with SEC
20 Dec 12
Ownership
4
IMMUCELL / David Scott Tomsche ownership change
16 Jun 22
4
IMMUCELL / David Cunningham ownership change
14 Jun 22
4/A
IMMUCELL / David Scott Tomsche ownership change
18 May 22
4
IMMUCELL / JOSEPH H CRABB ownership change
18 May 22
4
IMMUCELL / David Scott Tomsche ownership change
18 May 22
4
IMMUCELL / JOSEPH H CRABB ownership change
14 Mar 22
4
IMMUCELL / Bobbi Jo Brockmann ownership change
9 Feb 22
4
IMMUCELL / MICHAEL F BRIGHAM ownership change
9 Feb 22
4
IMMUCELL / Elizabeth Luttrell Williams ownership change
9 Feb 22
4
IMMUCELL / Gloria F Basse ownership change
25 Jun 21
Transcripts
2022 Q1
Earnings call transcript
13 May 22
2021 Q4
Earnings call transcript
23 Feb 22
2021 Q3
Earnings call transcript
16 Nov 21
2021 Q2
Earnings call transcript
13 Aug 21
2021 Q1
Earnings call transcript
14 May 21
2020 Q4
Earnings call transcript
23 Feb 21
2020 Q3
Earnings call transcript
13 Nov 20
2020 Q2
Earnings call transcript
13 Aug 20
2020 Q1
Earnings call transcript
14 May 20
2019 Q4
Earnings call transcript
19 Feb 20
Reddit threads
Daily Discussion Thread - August 11th, 2022
11 Aug 22
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Value Investors: Keith Gill explains
6 May 22
Daily Discussion Thread - February 22nd, 2022
22 Feb 22
Daily Discussion Thread - February 21st, 2022
21 Feb 22
What Are Your 2022 YOLOs?
24 Dec 21
Daily Discussion Thread - November 15th, 2021
15 Nov 21
Daily Discussion Thread - November 12th, 2021
12 Nov 21